$GMAB News

Guggenheim Maintains Buy on Genmab, Raises Price Target to $42

Genmab (GMAB) Q2 2026 Earnings Call Transcript

Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Genmab A/S Q2 Earnings Call Highlights

Genmab shares jump 8% after upbeat results prompt 2026 outlook raise

Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est

Genmab Announces Financial Results for the First Half of 2026

Genmab A/S 2026 Q2 - Results - Earnings Call Presentation

Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup

Genmab's H1 Preview: Darzalex Beats The Sales Outlook

TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab’s TEPKINLY + R2 Wins EU Approval As First Bispecific Therapy For Relapsed Follicular Lymphoma Following Phase 3 Trial Success

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

Genmab Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Objective, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $38 Price Target

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Major Shareholder Announcement